Bayer: positive study on finerenone in cardiology
(CercleFinance.com) - Bayer reports that results from a Phase III study showed that finerenone (Kerendia/Firialta) significantly improved cardiovascular outcomes in heart failure patients with a left ventricular ejection fraction (LVEF) of 40% or more.
Compared with placebo, finerenone reduced the risk of cardiovascular death and heart failure-related events by 16% over a median period of 32 months.
The benefits observed were consistent across all patient subgroups, irrespective of background therapy or comorbidities, the laboratory says.
If approved, finerenone could become an important treatment for these patients, who currently have few effective therapeutic options.
The results of the study were presented at the 2024 European Society of Cardiology Congress and published in the New England Journal of Medicine.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Compared with placebo, finerenone reduced the risk of cardiovascular death and heart failure-related events by 16% over a median period of 32 months.
The benefits observed were consistent across all patient subgroups, irrespective of background therapy or comorbidities, the laboratory says.
If approved, finerenone could become an important treatment for these patients, who currently have few effective therapeutic options.
The results of the study were presented at the 2024 European Society of Cardiology Congress and published in the New England Journal of Medicine.
Copyright (c) 2024 CercleFinance.com. All rights reserved.